Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial

Autor: Kathleen M Mullane, Vicki A Morrison, Luis H Camacho, Ann Arvin, Shelly A McNeil, Jessie Durrand, Bernadette Campbell, Shu-Chih Su, Ivan S F Chan, Janie Parrino, Susan S Kaplan, Zoran Popmihajlov, Paula W Annunziato, S Cerana, MO Dictar, P Bonvehi, JP Tregnaghi, L Fein, D Ashley, M Singh, T Hayes, G Playford, O Morrissey, J Thaler, T Kuehr, R Greil, M Pecherstorfer, L Duck, K Van Eygen, M Aoun, B De Prijck, FA Franke, CHE Barrios, AVA Mendes, SV Serrano, RF Garcia, F Moore, JFC Camargo, LA Pires, RS Alves, A Radinov, K Oreshkov, V Minchev, AI Hubenova, T Koynova, I Ivanov, B Rabotilova, PA Petrov, P Chilingirov, S Karanikolov, J Raynov, D Grimard, S McNeil, D Kumar, LM Larratt, K Weiss, R Delage, FJ Diaz-Mitoma, PO Cano, F Couture, P Carvajal, A Yepes, R Torres Ulloa, P Fardella, C Caglevic, C Rojas, E Orellana, P Gonzalez, A Acevedo, KM Galvez, ME Gonzalez, S Franco, JG Restrepo, CA Rojas, C Bonilla, LE Florez, AV Ospina, R Manneh, R Zorica, DV Vrdoljak, M Samarzija, L Petruzelka, J Vydra, J Mayer, D Cibula, J Prausova, G Paulson, M Ontaneda, K Palk, A Vahlberg, R Rooneem, F Galtier, D Postil, F Lucht, F Laine, O Launay, H Laurichesse, X Duval, OA Cornely, B Camerer, J Panse, M Zaiss, H-G Derigs, H Menzel, M Verbeek, V Georgoulias, D Mavroudis, A Anagnostopoulos, E Terpos, D Cortes, J Umanzor, S Bejarano, RW Galeano, RSM Wong, P Hui, P Pedrazzoli, L Ruggeri, F Aversa, A Bosi, G Gentile, A Rambaldi, A Contu, L Marei, A Abbadi, W Hayajneh, J Kattan, F Farhat, G Chahine, J Rutkauskiene, LJ Marfil Rivera, YA Lopez Chuken, H Franco Villarreal, J Lopez Hernandez, H Blacklock, RI Lopez, R Alvarez, AM Gomez, TS Quintana, MDC Moreno Larrea, SJ Zorrilla, E Alarcon, FCA Samanez, PB Caguioa, BJ Tiangco, EM Mora, RD Betancourt-Garcia, D Hallman-Navarro, LJ Feliciano-Lopez, HA Velez-Cortes, F Cabanillas, DE Ganea, TE Ciuleanu, DG Ghizdavescu, L Miron, CL Cebotaru, CI Cainap, R Anghel, MV Dvorkin, OA Gladkov, NV Fadeeva, AA Kuzmin, ON Lipatov, II Zbarskaya, FS Akhmetzyanov, IV Litvinov, BV Afanasyev, M Cherenkova, D Lioznov, IA Lisukov, YA Smirnova, S Kolomietz, H Halawani, YT Goh, L Drgona, J Chudej, M Matejkova, M Reckova, BL Rapoport, WM Szpak, DR Malan, N Jonas, CW Jung, DG Lee, SS Yoon, J Lopez Jimenez, I Duran Martinez, JF Rodriguez Moreno, C Solano Vercet, R de la Camara, M Batlle Massana, S-P Yeh, C-Y Chen, H-H Chou, C-M Tsai, C-H Chiu, N Siritanaratkul, L Norasetthada, V Sriuranpong, K Seetalarom, H Akan, F Dane, MA Ozcan, GH Ozsan, SF Kalayoglu Besisik, A Cagatay, S Yalcin, A Peniket, SR Mullan, KM Dakhil, K Sivarajan, JJ-G Suh, A Sehgal, F Marquez, EG Gomez, MR Mullane, WL Skinner, RJ Behrens, DR Trevarthe, MA Mazurczak, EA Lambiase, CA Vidal, SY Anac, GA Rodrigues, B Baltz, R Boccia, MS Wertheim, CS Holladay, D Zenk, W Fusselman, JL Wade III, AJ Jaslowsk, J Keegan, MO Robinson, RS Go, J Farnen, B Amin, D Jurgens, GF Risi, PG Beatty, T Naqvi, S Parshad, VL Hansen, M Ahmed, PD Steen, S Badarinath, A Dekker, MA Scouros, DE Young, W Graydon Harker, SD Kendall, ML Citron, S Chedid, JG Posada, MK Gupta, S Rafiyath, J Buechler-Price, S Sreenivasappa, CH Chay, JM Burke, SE Young, A Mahmood, JW Kugler, G Gerstner, J Fuloria, ND Belman, R Geller, J Nieva, BP Whittenberger, BMY Wong, TP Cescon, G Abesada-Terk, MJ Guarino, A Zweibach, EN Ibrahim, G Takahashi, MA Garrison, RB Mowat, BS Choi, IA Oliff, J Singh, KA Guter, K Ayrons, KM Rowland, SJ Noga, SB Rao, A Columbie, MT Nualart, GR Cecchi, LT Campos, M Mohebtash, MR Flores, R Rothstein-Rubin, BM O'Connor, G Soori, M Knapp, FG Miranda, BW Goodgame, M Kassem, R Belani, S Sharma, T Ortiz, HL Sonneborn, AB Markowitz, D Wilbur, E Meiri, VS Koo, HS Jhangiani, L Wong, S Sanani, SJ Lawrence, CM Jones, C Murray, C Papageorgiou, JS Gurtler, JL Ascensao, ML Venigalla, M D'Andrea, C De Las Casas, DJ Haile, FU Qazi, JL Santander, MR Thomas, VP Rao, M Craig, RJ Garg, R Robles, RM Lyons, RK Stegemoller, S Goel, S Garg, P Lowry, C Lynch, B Lash, T Repka, J Baker, BS Goueli, TC Campbell, DA Van Echo, YJ Lee, EA Reyes, FM Senecal, G Donnelly, P Byeff, R Weiss, T Reid, E Roeland, A Goel, DM Prow, DS Brandt, HG Kaplan, JE Payne, MG Boeckh, PJ Rosen, RR Mena, R Khan, RF Betts, SA Sharp, VA Morrison, D Fitz-Patrick, J Congdon, N Erickson, R Abbasi, S Henderson, A Mehdi, EJ Wos, E Rehmus, L Beltzer, RA Tamayo, T Mahmood, AC Reboli, A Moore, JM Brown, J Cruz, DP Quick, JL Potz, KW Kotz, M Hutchins, NM Chowhan, YD Devabhaktuni, P Braly, RA Berenguer, SC Shambaugh, TJ O'Rourke, WA Conkright, CF Winkler, FEK Addo, JP Duic, KP High, ME Kutner, R Collins, DR Carrizosa, DJ Perry, E Kailath, N Rosen, R Sotolongo, S Shoham, T Chen

Summary Background Patients who are immunocompromised because of malignancy have an increased risk of herpes zoster and herpes zoster-related complications. We aimed to investigate the efficacy and safety of an inactivated varicella zoster virus (VZV

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9512b960de076ec44f04d635a16f9143
http://hdl.handle.net/11573/1331005

Modeling the durability of ZOSTAVAX® vaccine efficacy in people ≥60 years of age

Autor: Jane H. Zhang, Robbin F. Itzler, Camilo J. Acosta, Erik J. Dasbach, Gary R. Johnson, Ruifeng Xu, Robert F. Betts, James M. Pellissier, Vicki A. Morrison, Ivan S. F. Chan, Xiaoming Li

Publikováno v: Vaccine. 33:1499-1505

Since 2006, the vaccine, ZOSTAVAX(®), has been licensed to prevent herpes zoster. Only limited clinical follow-up data are available to evaluate duration of protection, an important consideration when developing HZ vaccination policy recommendations

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e782c21eff1331bcc6d3116fba5f6a8a
https://doi.org/10.1016/j.vaccine.2014.10.039

Confidence-Interval Construction for Rate Ratio in Matched-Pair Studies with Incomplete Data

Autor: Hui-Qiong Li, Guo-Liang Tian, Ivan S. F. Chan, Nian-Sheng Tang, Man-Lai Tang

Publikováno v: Journal of Biopharmaceutical Statistics. 24:546-568

Matched-pair design is often used in clinical trials to increase the efficiency of establishing equivalence between two treatments with binary outcomes. In this article, we consider such a design based on rate ratio in the presence of incomplete data

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4ceba7dd1e88eb1b9a47f92cca2db56
https://doi.org/10.1080/10543406.2014.888438

Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster

Autor: Vicki A, Morrison, Michael N, Oxman, Myron J, Levin, Kenneth E, Schmader, John C, Guatelli, Robert F, Betts, Larry D, Gelb, Constance T, Pachucki, Susan K, Keay, Barbara, Menzies, Marie R, Griffin, Carol A, Kauffman, Adriana R, Marques, John F, Toney, Michael S, Simberkoff, Richard, Serrao, Robert D, Arbeit, John W, Gnann, Richard N, Greenberg, Mark, Holodniy, Wendy A, Keitel, Shingshing S, Yeh, Larry E, Davis, George E, Crawford, Kathy M, Neuzil, Gary R, Johnson, Jane H, Zhang, Rith, Harbecke, Ivan S F, Chan, Paul M, Keller, Heather M, Williams, Kathy D, Boardman, Jeffrey L, Silber, Paula W, Annunziato, J F, Toney

Publikováno v: The Journal of Infectious Diseases. 208:559-563

Background. After completion of the Shingles Prevention Study (SPS; Department of Veterans Affairs Cooperative Studies Program Number 403), SPS participants who had initially received placebo were offered investigational zoster vaccine without charge

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e40304f8a8b1a4814f972bf828f6742
https://doi.org/10.1093/infdis/jit182

Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies

Autor: Eva Kimby, Marco F. Pagnoni, Janie Parrino, Ivan S. F. Chan, Shelly A. McNeil, Steven J. Lawrence, Yanli Zhao, Susan S. Kaplan, Jon E. Stek

Publikováno v: Vaccine. 35(14)

Background Immunocompromised patients can experience significant morbidity and occasional mortality from complications associated with herpes zoster (HZ), but live attenuated HZ vaccine is contraindicated for these patients. Inactivated zoster vaccin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9536e4b669ed1dc3234cd7f8e97f721b
https://pubmed.ncbi.nlm.nih.gov/28268074